Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.1K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.1K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

4.6K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.6K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

1.1K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.1K
Intrinsically Disordered Proteins02:18

Intrinsically Disordered Proteins

19.6K
Intrinsically disordered proteins are a group of proteins that do not fold into specific three-dimensional structures. Their structural flexibility allows them to complement ordered proteins to perform functions that are inaccessible to rigid structures. They are more common in eukaryotes than prokaryotes and may either be exclusively intrinsically disordered or hybrid proteins, consisting of a mix of ordered and disordered regions. The absence of a rigid structure in these proteins can be...
19.6K
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

699
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
699
Bone Disorders01:29

Bone Disorders

5.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging Substances and Perinatal Health: A Narrative Review.

Obstetrics and gynecology·2025
Same author

Viscoelastic coagulation monitoring parameters in cats with acute arterial thromboembolism.

Journal of veterinary internal medicine·2024
Same author

Improved Maternal and Infant Outcomes with Serial, Self-Reported Early Prenatal Substance Use Screening.

Maternal and child health journal·2021
Same author

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Neonatal Cord Blood After Vaccination in Pregnancy.

Obstetrics and gynecology·2021
Same author

Opioid prescribing trends in postpartum women: a multicenter study.

American journal of obstetrics & gynecology MFM·2020
Same author

Hospital care for opioid use disorder in pregnancy: Challenges and opportunities identified from a Minnesota survey.

Women's health (London, England)·2020

Related Experiment Video

Updated: Feb 10, 2026

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

3.8K

Opioid Use Disorders and Pregnancy.

Amanda J Johnson1, Cresta W Jones2

  • 1Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA.

Obstetrics and Gynecology Clinics of North America
|May 12, 2018
PubMed
Summary

Opioid use disorder in pregnancy increases risks, but medication-assisted treatment can optimize outcomes. Neonatal abstinence syndrome and poor fetal growth remain challenges even with treatment.

Keywords:
BuprenorphineMethadoneNeonatal abstinence syndromeOpioid use disorderPregnancy

More Related Videos

A Novel Use of Three-dimensional High-frequency Ultrasonography for Early Pregnancy Characterization in the Mouse
07:04

A Novel Use of Three-dimensional High-frequency Ultrasonography for Early Pregnancy Characterization in the Mouse

Published on: October 24, 2017

8.9K
Transabdominal Ultrasound for Pregnancy Diagnosis in Reeves' Muntjac Deer
09:26

Transabdominal Ultrasound for Pregnancy Diagnosis in Reeves' Muntjac Deer

Published on: January 7, 2014

10.9K

Related Experiment Videos

Last Updated: Feb 10, 2026

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

3.8K
A Novel Use of Three-dimensional High-frequency Ultrasonography for Early Pregnancy Characterization in the Mouse
07:04

A Novel Use of Three-dimensional High-frequency Ultrasonography for Early Pregnancy Characterization in the Mouse

Published on: October 24, 2017

8.9K
Transabdominal Ultrasound for Pregnancy Diagnosis in Reeves' Muntjac Deer
09:26

Transabdominal Ultrasound for Pregnancy Diagnosis in Reeves' Muntjac Deer

Published on: January 7, 2014

10.9K

Area of Science:

  • Obstetrics and Gynecology
  • Addiction Medicine
  • Neonatal Health

Background:

  • Opioid use disorder (OUD) in pregnancy poses significant risks to both mother and fetus.
  • Untreated OUD is associated with severe maternal and neonatal complications.
  • Comprehensive care models are essential for managing OUD during pregnancy.

Purpose of the Study:

  • To review the risks associated with opioid use disorder in pregnancy.
  • To highlight the benefits of medication-assisted treatment (MAT) for pregnant individuals with OUD.
  • To discuss persistent complications despite maternal treatment.

Main Methods:

  • Literature review of current research on OUD in pregnancy.
  • Analysis of treatment guidelines for medication-assisted treatment (methadone, buprenorphine).
  • Examination of neonatal outcomes in treated and untreated pregnancies.

Main Results:

  • Medication-assisted treatment (methadone, buprenorphine) is recommended as part of comprehensive care.
  • MAT can mitigate some risks associated with untreated OUD during pregnancy.
  • Neonatal abstinence syndrome and poor fetal growth persist as significant complications.

Conclusions:

  • OUD in pregnancy requires specialized, comprehensive care.
  • Medication-assisted treatment is a cornerstone of optimizing outcomes.
  • Further research is needed to address persistent neonatal complications.